Nasdaq · Biotech stocks database
GHRS (GH Research PLC) stock: $19.36, $1.33B market cap, $246.2M cash, $1.08B EV, $1.20B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
We are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. Our initial focus is on developing our novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression, or TRD.
Source: 20-F FY2025 via SEC EDGAR
| Cash | $246.2M |
|---|---|
| Debt | $0.0M |
| Net cash | $246.2M |
| Enterprise value | $1,081.0M |
| Basic shares | 62.0M shares |
| Fully diluted shares | 62.0M shares |
| Fully diluted market cap | $1,200.9M |
| Cash per share | $3.97 |
| Quarterly burn | $12.3M |
| Cash runway | 20.0 quarters |
Cash figures as of 2025-12-31. Database snapshot: 2026-11-11.
Cap table as of 2025-12-31.
Loading GHRS daily closes…